Publication | Closed Access

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

Recurrent And/orMalignant DiseasePlatinum-refractory HeadMedicinePhase Ii StudyHead And Neck CancerDermatologyCancer TreatmentNeck OncologyOncologyRadiation Oncology